July 05, 2024
Japanese patent granted for selected compounds for chronic wound therapy
Japanese patent granted for selected compounds for chronic wound therapy
FORCE REPAIR update with an animated illustration of the EU project and a new online interview with Gabriela Cabral from the Akribes team
The FORCE REPAIR Team has produced an animated video to explain how #FORCEREPAIR strives to advance chronic wound management by developing a smart, multi-functional, and cost-effective 3D-printed wound dressing.
See also the new interview online: “Meet Gabriela Cabral” from the Akribes team
https://www.forcerepair-wounds.eu/interviews#gabriela-cabral
EU patent granted for selected compounds for chronic wound therapy
US patent granted for selected compounds for chronic wound therapy
US patent granted for theranostic assay platform
Australian patent granted for theranostic assay platform
Kick-off day for new EU Project FORCE REPAIR: Innovating Chronic Wound Treatment
As a member of a multi-disciplinary and multi-national consortium, Akribes was granted funding by the European Union for the Horizon Europe project entitled FORCE REPAIR, the acronym for “smart and multiFunctional 3D printable prO-Regenerative biologiCal matrix modulating mEchanotRansduction as advancEd theraPy to treAt skIn chRonic wounds.”
The goal of this ambitious project is to improve chronic wound treatment with customized wound dressings by 3D-printing of functionalized bio-inks to relieve skin tension, fight infection, reduce inflammation and support regeneration of healthy tissue.
Please see the FORCE_REPAIR_Press release for more details, and follow the project on the website https://forecepair-wounds.eu and the FORCE REPAIR LinkedIn account.
Japanese patent granted for theranostic assay platform
Chinese patent granted for theranostic assay platform
TÜV Süd granted an ISO 13485:2016 Certificate for the Akribes Quality Management System (QMS)
The QMS at Akribes complies with the DIN EN ISO13485:2016 standard for medical devices. The certificate covers the scope of “Design and Development, Production and Sales of lab-on-a-chip devices and IVD software for diagnostics and therapy recommendation for chronic/non-healing wounds.